8-K: Senseonics Reports Third Quarter 2024 Results, Highlights Eversense 365 Approval and Launch

Senseonics announced its third quarter 2024 financial results, highlighted by the FDA approval and initial commercial launch of its Eversense 365 continuous glucose monitoring system.

Summary

• Senseonics reported a total revenue of $4.3 million for the third quarter of 2024, a decrease from $6.1 million in the same period of 2023.
• The company experienced a gross loss of $4.1 million in Q3 2024, compared to a gross profit of $1.2 million in Q3 2023, primarily due to $4.8 million in one-time charges related to the transition from Eversense E3 to Eversense 365.
• Net loss for the quarter was $24.0 million, or $0.04 per share, which is similar to the net loss of $24.1 million in the third quarter of 2023.
• The company's cash, cash equivalents, restricted cash, and short-term investments totaled $74.8 million as of September 30, 2024, with outstanding debt of $55.9 million.
• Senseonics expects full-year 2024 global net revenue to be approximately $22 million and anticipates more than doubling U.S. new patient starts and increasing the global installed base by approximately 50% compared to 2023.
• The company has also executed a restructuring process with a target cash operating expense reduction of $10 million in 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the FDA approval and launch of Eversense 365 are positive, the financial results show a significant decrease in revenue and a gross loss. The company's future outlook is optimistic, but there are still risks and uncertainties.

Positives

• The FDA approval of Eversense 365 is a major achievement, positioning Senseonics as the world's first and only 365-day CGM.
• The initial commercial launch of Eversense 365 has generated strong early interest from clinicians and healthcare providers.
• The partnership with Mercy health system provides a significant opportunity for patient adoption.
• The acquisition of NPG assets will enhance patient access and convenience.
• The recent equity offerings have strengthened the company's balance sheet and extended its cash runway.
• The restructuring process is expected to reduce operating expenses by $10 million in 2025.
• Ascensia Diabetes Care is strongly committed to the successful launch of Eversense 365.

Negatives

• Total revenue decreased to $4.3 million in Q3 2024 from $6.1 million in Q3 2023.
• The company reported a gross loss of $4.1 million in Q3 2024, compared to a gross profit of $1.2 million in Q3 2023.
• The decrease in gross profit was primarily driven by one-time charges of $4.8 million associated with the transition from Eversense E3 to Eversense 365.
• Sales and marketing and general and administrative expenses increased by $0.9 million year-over-year, to $8.3 million.
• U.S. revenue decreased to $2.4 million in Q3 2024 from $3.9 million in the prior year period.
• Revenue outside the U.S. decreased to $1.9 million in Q3 2024 from $2.2 million in the prior year period.

Risks

• The company faces uncertainties in the execution of its commercialization partnership with Ascensia Diabetes Care.
• There are uncertainties in insurer, regulatory, and administrative processes and decisions.
• The development and roll-out of new technology and solutions carry inherent uncertainties.
• Finalizing integration and commercial terms with health systems and other partners presents challenges.
• The ongoing commercialization of the Eversense product and expansion of activities are subject to uncertainties.
• The current economic environment poses risks to the company's performance.

Future Outlook

Senseonics anticipates a transformational 2025, driven by the launch of Eversense 365, increased patient starts, and cost reductions from restructuring. The company expects full-year 2024 global net revenue to be approximately $22 million, with sales accelerating in the fourth quarter.

Management Comments

• Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, stated that the FDA approval of Eversense 365 and the first commercial patient insertion mark a significant achievement.
• Tim Goodnow also noted that the company received the highest influx of inquiries in its history in the first week after approval.
• Brian Hansen, President of CGM at Ascensia Diabetes Care, emphasized Ascensia's commitment to providing high-quality products and the unique value proposition of Eversense 365.

Industry Context

This announcement is significant in the competitive CGM market, as Senseonics is the first to offer a 365-day implantable sensor. The partnership with Ascensia and the initial adoption by Mercy health system are key to the company's success in this space. The transition from the E3 to the 365 product is a major shift in the company's product offering.

Comparison to Industry Standards

• Senseonics' Eversense 365 is unique in the CGM market with its 365-day sensor duration, differentiating it from competitors like Dexcom and Abbott, which offer shorter-term sensors.
• Dexcom's G7 and Abbott's Freestyle Libre are leading competitors in the CGM market, but they require more frequent sensor replacements.
• The partnership with Ascensia is similar to other distribution agreements in the medical device industry, but the long-term nature of the Eversense 365 sensor provides a unique value proposition.
• The Mercy health system collaboration is a significant step for Senseonics, as it provides a large-scale opportunity for patient adoption, similar to how other medical device companies partner with large healthcare providers.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and gross loss in Q3 2024, but encouraged by the FDA approval and future outlook.
• Employees may be affected by the restructuring process, but the company's growth prospects could provide opportunities.
• Patients with diabetes will benefit from the availability of the Eversense 365 system.
• Ascensia Diabetes Care will benefit from the commercialization of Eversense 365.
• Healthcare providers will have a new option for managing their patients' diabetes.

Next Steps

• Senseonics will continue the commercial launch of Eversense 365.
• The company will focus on transitioning U.S. patients to Eversense 365.
• Senseonics will work with Ascensia to ensure a successful launch.
• The company will implement its restructuring plan to reduce operating expenses.
• Senseonics will continue to expand its global installed base.

Key Dates

Keywords

Eversense 365, Continuous Glucose Monitoring, CGM, Diabetes, Medical Technology, Ascensia Diabetes Care, FDA Approval, Financial Results, Restructuring, Revenue